Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
In fit men, mortality lower in smokers with lung cancer, lung cancer risk lower in former smokers.
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
No significant differences in PROs were observed among patients treated with subsequent durvalumab after chemoradiation therapy for stage III unresectable NSCLC compared with those who received subsequent placebo.
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
